Which has stronger valuation & earnings, GALT or SVRA?

Savara is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.43 N/A Savara N/A N/A -$118.84M -$0.58 N/A

Is GALT or SVRA more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -176.83% Savara N/A -90.28% -68.95%

Does the media prefer GALT or SVRA?

In the previous week, Galectin Therapeutics had 2 more articles in the media than Savara. MarketBeat recorded 4 mentions for Galectin Therapeutics and 2 mentions for Savara. Savara's average media sentiment score of 1.84 beat Galectin Therapeutics' score of 0.80 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to KURA or GALT?

In the previous week, Kura Oncology had 4 more articles in the media than Galectin Therapeutics. MarketBeat recorded 8 mentions for Kura Oncology and 4 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.80 beat Kura Oncology's score of 0.43 indicating that Galectin Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Galectin Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, GALT or SANA?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.43 N/A Sana Biotechnology N/A N/A -$244.17M -$0.76 N/A

Is GALT or SANA more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -176.83% Sana Biotechnology N/A -103.02% -39.16%

Does the media refer more to GALT or SANA?

In the previous week, Sana Biotechnology had 4 more articles in the media than Galectin Therapeutics. MarketBeat recorded 8 mentions for Sana Biotechnology and 4 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.80 beat Sana Biotechnology's score of 0.59 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AVTX or GALT more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -58.03% -48.22% Galectin Therapeutics N/A N/A -176.83%

Does the media favor AVTX or GALT?

In the previous week, Avalo Therapeutics had 6 more articles in the media than Galectin Therapeutics. MarketBeat recorded 10 mentions for Avalo Therapeutics and 4 mentions for Galectin Therapeutics. Avalo Therapeutics' average media sentiment score of 0.83 beat Galectin Therapeutics' score of 0.80 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, GALT or SLDB?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.43 N/A Solid Biosciences N/A N/A -$174.32M -$1.91 N/A

Is GALT or SLDB more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -176.83% Solid Biosciences N/A -71.35% -60.58%

Does the media favor GALT or SLDB?

In the previous week, Galectin Therapeutics and Galectin Therapeutics both had 4 articles in the media. Solid Biosciences' average media sentiment score of 0.91 beat Galectin Therapeutics' score of 0.80 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Galectin Therapeutics (GALT) Competitors

$3.91 +0.01 (+0.26%)

As of 09/11/2026 04:00 PM Eastern

Compare

GALT vs. SVRA, KURA, SANA, AVTX, and SLDB

Should you buy Galectin Therapeutics stock or one of its competitors? Galectin Therapeutics's main competitors and comparable companies include Savara (SVRA), Kura Oncology (KURA), Sana Biotechnology (SANA), Avalo Therapeutics (AVTX), and Solid Biosciences (SLDB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Galectin Therapeutics compare to Savara?

Galectin Therapeutics (NASDAQ:GALT) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Galectin Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Savara has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Galectin Therapeutics' return on equity of 0.00% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Savara	N/A	-90.28%	-68.95%

Galectin Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 181.33%. Savara has a consensus target price of $10.00, suggesting a potential upside of 88.68%. Given Galectin Therapeutics' higher possible upside, equities research analysts clearly believe Galectin Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Savara is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

In the previous week, Galectin Therapeutics had 2 more articles in the media than Savara. MarketBeat recorded 4 mentions for Galectin Therapeutics and 2 mentions for Savara. Savara's average media sentiment score of 1.84 beat Galectin Therapeutics' score of 0.80 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Galectin Therapeutics beats Savara on 8 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Galectin Therapeutics has lower revenue, but higher earnings than Kura Oncology. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	15.02	-$278.67M	-$3.37	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A

Kura Oncology currently has a consensus price target of $25.40, suggesting a potential upside of 123.00%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 181.33%. Given Galectin Therapeutics' higher possible upside, analysts plainly believe Galectin Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Galectin Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Galectin Therapeutics' return on equity of 0.00% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Galectin Therapeutics	N/A	N/A	-176.83%

In the previous week, Kura Oncology had 4 more articles in the media than Galectin Therapeutics. MarketBeat recorded 8 mentions for Kura Oncology and 4 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.80 beat Kura Oncology's score of 0.43 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Galectin Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kura Oncology has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

11.7% of Galectin Therapeutics shares are held by institutional investors. 7.6% of Kura Oncology shares are held by company insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Galectin Therapeutics beats Kura Oncology on 8 of the 15 factors compared between the two stocks.

How does Galectin Therapeutics compare to Sana Biotechnology?

Galectin Therapeutics (NASDAQ:GALT) and Sana Biotechnology (NASDAQ:SANA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Galectin Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 181.33%. Sana Biotechnology has a consensus price target of $9.33, indicating a potential upside of 198.19%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Sana Biotechnology had 4 more articles in the media than Galectin Therapeutics. MarketBeat recorded 8 mentions for Sana Biotechnology and 4 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.80 beat Sana Biotechnology's score of 0.59 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

Galectin Therapeutics' return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Sana Biotechnology	N/A	-103.02%	-39.16%

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Galectin Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market.

Summary

Sana Biotechnology beats Galectin Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Galectin Therapeutics has lower revenue, but higher earnings than Avalo Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	14,408.59	-$78.26M	-$4.37	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A

In the previous week, Avalo Therapeutics had 6 more articles in the media than Galectin Therapeutics. MarketBeat recorded 10 mentions for Avalo Therapeutics and 4 mentions for Galectin Therapeutics. Avalo Therapeutics' average media sentiment score of 0.83 beat Galectin Therapeutics' score of 0.80 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Galectin Therapeutics' return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Galectin Therapeutics	N/A	N/A	-176.83%

Avalo Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Avalo Therapeutics presently has a consensus target price of $45.10, indicating a potential upside of 179.78%. Galectin Therapeutics has a consensus target price of $11.00, indicating a potential upside of 181.33%. Given Galectin Therapeutics' higher possible upside, analysts clearly believe Galectin Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Avalo Therapeutics beats Galectin Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to Solid Biosciences?

Galectin Therapeutics (NASDAQ:GALT) and Solid Biosciences (NASDAQ:SLDB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

Galectin Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 181.33%. Solid Biosciences has a consensus price target of $18.18, suggesting a potential upside of 108.99%. Given Galectin Therapeutics' higher possible upside, analysts clearly believe Galectin Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Galectin Therapeutics and Galectin Therapeutics both had 4 articles in the media. Solid Biosciences' average media sentiment score of 0.91 beat Galectin Therapeutics' score of 0.80 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Galectin Therapeutics has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market.

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Galectin Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Solid Biosciences	N/A	-71.35%	-60.58%

Summary

Solid Biosciences beats Galectin Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Galectin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GALT vs. The Competition

Export

Metric	Galectin Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$257.50M	$3.85B	$7.15B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	-9.09	14.18	274.94	25.36
Price / Sales	N/A	1,374.99	686.57	116.78
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	-1.96	15.12	10.33	6.20
Net Income	-$30.84M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-15.18%	-4.34%	-3.32%	-2.35%
1 Month Performance	10.76%	0.54%	-0.53%	-3.23%
1 Year Performance	-27.19%	40.74%	23.51%	8.79%

Galectin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GALT Galectin Therapeutics	1.9524 of 5 stars	$3.91 +0.3%	$11.00 +181.3%	-27.2%	$257.50M	N/A	N/A	9	News Coverage Positive News
SVRA Savara	2.1506 of 5 stars	$5.57 +3.6%	$10.14 +82.2%	+48.9%	$1.15B	N/A	N/A	20	Positive News
KURA Kura Oncology	3.5139 of 5 stars	$12.79 -3.4%	$25.40 +98.5%	+39.1%	$1.14B	$67.48M	N/A	130
SANA Sana Biotechnology	2.6701 of 5 stars	$3.78 -1.9%	$9.33 +147.2%	-2.8%	$1.13B	N/A	N/A	380	News Coverage
AVTX Avalo Therapeutics	3.4565 of 5 stars	$20.13 +4.7%	$45.10 +124.1%	+51.4%	$1.07B	$60K	N/A	40	News Coverage Analyst Downgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GALT) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galectin Therapeutics (GALT) Competitors

GALT vs. SVRA, KURA, SANA, AVTX, and SLDB

How does Galectin Therapeutics compare to Savara?

Summary

How does Galectin Therapeutics compare to Kura Oncology?

Summary

How does Galectin Therapeutics compare to Sana Biotechnology?

Summary

How does Galectin Therapeutics compare to Avalo Therapeutics?

Summary

How does Galectin Therapeutics compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galectin Therapeutics (GALT) Competitors

GALT vs. SVRA, KURA, SANA, AVTX, and SLDB

How does Galectin Therapeutics compare to Savara?

Which has more risk & volatility, GALT or SVRA?

Do institutionals and insiders believe in GALT or SVRA?

Is GALT or SVRA more profitable?

Do analysts rate GALT or SVRA?

Which has stronger valuation & earnings, GALT or SVRA?

Does the media prefer GALT or SVRA?

Summary

How does Galectin Therapeutics compare to Kura Oncology?

Which has higher earnings and valuation, KURA or GALT?

Do analysts prefer KURA or GALT?

Is KURA or GALT more profitable?

Does the media refer more to KURA or GALT?

Which has more risk & volatility, KURA or GALT?

Do insiders & institutionals hold more shares of KURA or GALT?

Summary

How does Galectin Therapeutics compare to Sana Biotechnology?

Do analysts rate GALT or SANA?

Does the media refer more to GALT or SANA?

Which has better valuation and earnings, GALT or SANA?

Is GALT or SANA more profitable?

Do institutionals and insiders have more ownership in GALT or SANA?

Which has more risk & volatility, GALT or SANA?

Summary

How does Galectin Therapeutics compare to Avalo Therapeutics?

Which has higher earnings & valuation, AVTX or GALT?

Does the media favor AVTX or GALT?

Is AVTX or GALT more profitable?

Which has more volatility and risk, AVTX or GALT?

Do analysts recommend AVTX or GALT?

Do insiders & institutionals have more ownership in AVTX or GALT?

Summary

How does Galectin Therapeutics compare to Solid Biosciences?

Which has preferable earnings & valuation, GALT or SLDB?

Do analysts recommend GALT or SLDB?

Does the media favor GALT or SLDB?

Which has more volatility & risk, GALT or SLDB?

Do institutionals & insiders hold more shares of GALT or SLDB?

Is GALT or SLDB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools